Corteva Inc
CTVA: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$32.00 | Nqnc | Jqvvrfzw |
Maintaining $70 FVE as Corteva Expands Biologicals Portfolio With Stoller Deal; Shares Fairly Valued
Having updated our model to include the Stoller acquisition, we maintain our $70 per share fair value estimate for Corteva as the deal is value neutral. Our wide-moat rating is also unchanged. The $1.2 billion cash acquisition deal values Stoller at a 12 times enterprise value/EBITDA multiple. Based on PitchBook data for comparable deals, we view this multiple as in line with the average of other deals.